Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12621000113853
Ethics application status
Approved
Date submitted
23/11/2020
Date registered
4/02/2021
Date last updated
28/07/2024
Date data sharing statement initially provided
4/02/2021
Date results provided
28/07/2024
Type of registration
Prospectively registered

Titles & IDs
Public title
Effect of mepolizumab on alternative functions of eosinophils in severe eosinophilic asthma
Scientific title
A single-site cross-sectional cohort study with longitudinal follow-up to investigate the effect of mepolizumab treatment on homeostatic and induced eosinophils, eosinophil extracellular traps, mast cells and basophils in people with severe eosinophilic asthma
Secondary ID [1] 302749 0
Nil known
Universal Trial Number (UTN)
Trial acronym
ALTEOS
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Severe asthma 319693 0
Condition category
Condition code
Respiratory 317620 317620 0 0
Asthma
Inflammatory and Immune System 317621 317621 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Observational
Patient registry
False
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
A cross-sectional observational study will be conducted in participants with stable severe asthma.

Participants will be categorized into three groups:
1. Stable severe asthma not treated with biologics without elevated blood eosinophils (non-eosinophilic)
2. Stable severe asthma not treated with biologics with elevated blood eosinophils (eosinophilic)
3. Stable severe asthma currently receiving mepolizumab treatment

All participants in groups 1,2 and 3 will attend a cross-sectional study visit. Participants in group 2 who commence mepolizumab (Nucala) or benralizumab (Fasenra) treatment as part of their routine clinical care subsequent to the initial cross-sectional study visit will also attend longitudinal follow up study visits at >4 weeks post treatment commencement and >6 months post treatment commencement.

Each study visit (cross-sectional and longitudinal) will involve collection of blood and induced sputum samples, spirometry (lung function) tests, measurement of height and weight. The participant will also complete some questionnaires to gain information about general health or quality of life, medical history and medications and asthma symptoms. Study visits are anticipated to be 1-2 hours in duration.

All participants will consent to:
A. Completing the tests involved in the study
B. Completing questionnaires to obtain research data
C. Allowing research personnel to access their medical record

Participants may optionally consent to:
D. Storage of biospecimens for use in future research studies relating to asthma and respiratory disease.
Intervention code [1] 319034 0
Not applicable
Comparator / control treatment
For cross-sectional analyses, comparisons will be made between participant groups 1, 2 and 3:

1. Stable severe asthma not treated with biologics without elevated blood eosinophils (non-eosinophilic)
2. Stable severe asthma not treated with biologics with elevated blood eosinophils (eosinophilic)
3. Stable severe asthma currently receiving mepolizumab treatment

For longitudinal analyses of participants in group 2 who commence mepolizumab or benralizumab as part of their routine clinical care after the cross sectional visit, measures made pre- and post- commencement of these treatments will be compared.
Control group
Active

Outcomes
Primary outcome [1] 325663 0
Comparison of blood eosinophil subpopulation number between severe non-eosinophilic asthma, severe eosinophilic asthma, severe eosinophilic asthma.
Timepoint [1] 325663 0
Cross-sectional (baseline/initial visit for all participants)
Primary outcome [2] 326172 0
Comparison of blood eosinophil subpopulation proportion between severe non-eosinophilic asthma, severe eosinophilic asthma, severe eosinophilic asthma.
Timepoint [2] 326172 0
Cross-sectional (baseline/initial visit for all participants)
Secondary outcome [1] 388724 0
Blood and sputum eosinophil subpopulations.
Timepoint [1] 388724 0
Cross-sectional (baseline/initial visit for all participants)
Secondary outcome [2] 390361 0
Extracellular trap formation in sputum slides and supernatant
Timepoint [2] 390361 0
Cross-sectional (baseline/initial visit for all participants)
Secondary outcome [3] 390362 0
Sputum and blood mast cell and basophil measures.
Timepoint [3] 390362 0
Cross-sectional (baseline/initial visit for all participants)
Secondary outcome [4] 390363 0
Blood and sputum eosinophil subpopulations.
Timepoint [4] 390363 0
Longitudinal (participants in group 2 at baseline/initial visit and at >4 weeks and >6 months post commencement of treatment)
Secondary outcome [5] 390364 0
Extracellular trap formation in sputum slides and supernatant
Timepoint [5] 390364 0
Longitudinal (participants in group 2 at baseline/initial visit and at >4 weeks and >6 months post commencement of treatment)
Secondary outcome [6] 390365 0
Sputum and blood mast cell and basophil measures.
Timepoint [6] 390365 0
Longitudinal (participants in group 2 at baseline/initial visit and at >4 weeks and >6 months post commencement of treatment)

Eligibility
Key inclusion criteria
1. Able to provide informed written consent
2. Adults (18 years or older) with doctor diagnosed severe asthma based on Global Initiative For Asthma (GINA) 2019 guidelines and PBS eligibility criteria for initiation of treatment of severe asthma with mepolizumab as follows:
a. Evidence or documented evidence of asthma defined by:
i. Forced expiratory volume (FEV1) reversibility greater than or equal to 12%, and greater than or equal to 200 mL at baseline within 30 minutes after administration of salbutamol (200 to 400 micrograms), OR
ii. Airway hyper-responsiveness defined as a greater than 20% decline in FEV1 during a direct bronchial provocation test or greater than 15% decline during an indirect bronchial provocation test, OR
iii. Peak expiratory flow (PEF) variability of greater than 15% between the two highest and two lowest peak expiratory flow rates during 14 days, OR
iv. Diagnosis of asthma from at least two physicians experienced in the management of patients with severe asthma

b. Asthma is uncontrolled* or not well-controlled^ despite adherence with optimized moderate to high dose inhaled corticosteroid-long-acting beta-2 agonist (ICS-LABA)# therapy and treatment of contributory factors, or that worsens when high dose treatment is decreased.
c. *Uncontrolled asthma includes one or both of the following:
i. Poor symptom control (frequent symptoms or reliever use, activity limited by asthma, night waking due to asthma)
ii. Exacerbations (1 or more in prior year) requiring oral corticosteroids (OCS), or serious exacerbations (1 or more in prior year) requiring hospitalization
^Not well-controlled asthma is defined by ACQ5 greater than or equal to 1.0 during study screening or at baseline visit (see O’Byrne PM, Reddel HK, Eriksson G et al. Measuring asthma control: a comparison of three classification systems. Eur Resp J. 2010;36:269-276 and Juniper EF, Bousquet J et al. Identifying ‘well-controlled’ and ‘not well-controlled’ asthma using the Asthma Control Questionnaire. Resp Med. 2006;100(4):616-621.)
d. # For GINA definition of moderate to high dose ICS see (https://ginasthma.org/wp-content/uploads/2019/04/GINA-2019-main-Pocket-Guide-wms.pdf)
3. Stable disease, defined by lack of respiratory infection, exacerbation of asthma or alteration of maintenance asthma medication dose in prior 4 weeks to visit.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Pregnancy/breastfeeding
- Participants currently receiving or having received in past 6 months treatment with benralizumab or omalizumab.
- No exacerbation of asthma in prior 4 weeks at screening.

Study design
Purpose
Natural history
Duration
Cross-sectional
Selection
Defined population
Timing
Prospective
Statistical methods / analysis
Cross-sectional study:

For cross-sectional analyses, comparisons will be made between participant groups 1, 2 and 3 as outlined above. We will perform ANOVA with pre-planned comparisons. Where appropriate, data will be log transformed prior to analysis. Where data are non-normally distributed, Kruskal-Wallis will be used for 3 group comparison.

Longitudinal study: For endpoints within the longitudinal study analysis will be performed comparing baseline visit with follow up visits.

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
1/03/2021
Actual
16/06/2021
Date of last participant enrolment
Anticipated
1/03/2023
Actual
3/08/2023
Date of last data collection
Anticipated
3/04/2023
Actual
3/08/2023
Sample size
Target
80
Accrual to date
Final
80
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 17983 0
John Hunter Hospital - New Lambton
Recruitment postcode(s) [1] 31941 0
2305 - New Lambton Heights

Funding & Sponsors
Funding source category [1] 307170 0
Commercial sector/Industry
Name [1] 307170 0
Glaxo Smith Kline
Country [1] 307170 0
United Kingdom
Primary sponsor type
University
Name
University of Newcastle
Address
University Drive
Callaghan NSW 2308
Country
Australia
Secondary sponsor category [1] 307765 0
None
Name [1] 307765 0
Address [1] 307765 0
Country [1] 307765 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 307284 0
Hunter New England Human Research Ethics Committee
Ethics committee address [1] 307284 0
Ethics committee country [1] 307284 0
Australia
Date submitted for ethics approval [1] 307284 0
20/11/2020
Approval date [1] 307284 0
03/02/2021
Ethics approval number [1] 307284 0
2020/ETH02930

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 106682 0
Dr Michael Fricker
Address 106682 0
Level 2, Hunter Medical Research Institute
1 Kookaburra Circuit, New Lambton Heights NSW 2305
Country 106682 0
Australia
Phone 106682 0
+61 2 4042 0207
Fax 106682 0
+61 2 4042 0046
Email 106682 0
[email protected]
Contact person for public queries
Name 106683 0
Michael Fricker
Address 106683 0
Level 2, Hunter Medical Research Institute
1 Kookaburra Circuit, New Lambton Heights NSW 2305
Country 106683 0
Australia
Phone 106683 0
+61 2 4042 0207
Fax 106683 0
+61 2 4042 0046
Email 106683 0
[email protected]
Contact person for scientific queries
Name 106684 0
Michael Fricker
Address 106684 0
Level 2, Hunter Medical Research Institute
1 Kookaburra Circuit, New Lambton Heights NSW 2305
Country 106684 0
Australia
Phone 106684 0
+61 2 4042 0207
Fax 106684 0
+61 2 4042 0046
Email 106684 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
Anonymised data underlying published results
When will data be available (start and end dates)?
For up to 5 years after publication
Available to whom?
Researchers who provide a methodologically sound proposal
Available for what types of analyses?
Any
How or where can data be obtained?
Written request for data must be approved by the PIs ([email protected])


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.